arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

SOLIGENIX, INC.

SNGX
$0.39 ▲ +0.01 (+2.71%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

SOLIGENIX, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.0M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -214.0%
FCF / Share $-1.98
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$119.37K
↓ -85.8%
Net Income Profit after all expenses
$-11.08M
↓ -34.0%
Operating Margin Operating profit as % of sales
-227.7%
↓ -31.7%
FCF / Share Free cash flow per share
$-1.98
↑ +60.9%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
8
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters